Intimation of Cessation of Director of the Company

01st August, 2026 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub: Intimation of Cessation of Director of the Company In continuation to our earlier letter dated 30th July, 2026 and as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby inform that Ameera Shah (DIN: 00208095) has completed her term as an Independent Director of the Company on 01-Aug-26, pursuant to which she ceased to be the Director of the Company. The details as required under Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, with respect to cessation are enclosed herewith as Annexure – A. You are requested to take the above on records. Thanking you, Yours sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Email – investorservices@torrentpharma.com Annexure A Particulars Details Reason for change viz. Ameera Shah has completed her term as an Independent appointment, reappointment, Director of the Company on 01st August, 2026, pursuant to resignation, removal, death or which she ceased to be the Director of the Company otherwise – completion of term Date of appointment / 01st August, 2026 reappointment / cessation (as applicable) & term of appointment/re-appointment Brief Profile (In case of Not Applicable appointment) Disclosure of relationships Not Applicable between directors (in case of appointment of Director) Email – investorservices@torrentpharma.com